PYM50028: Investigation of Cogane in Early-stage Parkinson's Disease (CONFIDENT-PD) Trial record 2 of 2 for: cogane This study has been completed. Sponsor: MANF: Amarantus BioSciences Announces Positive Data Comparing the Trophic Factors MANF and GDNF. GDNF treatment in Parkinson’s disease: time for controlled clinical trials? Restorative treatments for brain disorders are rare.
In neuroscience research, it is not uncommon to suggest that experimental treatment strategies may have great clinical potential. The rescue or regeneration of a few cultured neurones may be sufficient to entice such optimism. However, the path to a new clinical therapy is typically painstakingly long and difficult to navigate. sNN0031. Product Description sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain.
